Kera Capital Partners’s Virtus Biotech Clinical Trials ETF BBC Stock Holding History

Kera Capital Partners’s Portfolio BBC Stock Details BBC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.72M	Buy	89,364 +4,394	+5%	+$180K	0.46%	46
2025 Q4	$3.47M	Buy	+84,970	New	+$2.89M	0.43%	49

Other funds holding BBC

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

MCM

Militia Capital Management Austin, Texas $454M AUM

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

QCM

Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

APW

Aurora Private Wealth Rockaway, New Jersey $140M AUM

FTUS

Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

GAA

Global Assets Advisory Orlando, Florida $349M AUM 24.2% 1-Year Est. Return

Kera Capital Partners's BBC Position: Q1 2026 in Review

Kera Capital Partners increased its Virtus Biotech Clinical Trials ETF (BBC) stake by 5.2% in Q1 2026, buying an estimated $180K and bringing the position to 89,364 shares worth $3.72M. The position accounts for 0.46% of the portfolio, ranked #46.

Kera Capital Partners first reported a position in BBC in Q4 2025 and has held it in 2 quarters since. 20 funds tracked by Wall St. Rank hold BBC as of Q1 2026.

Kera Capital Partners held 89,364 shares of Virtus Biotech Clinical Trials ETF worth $3.72M as of Q1 2026.
Kera Capital Partners bought 4,394 Virtus Biotech Clinical Trials ETF shares in Q1 2026, an estimated $180K.
Virtus Biotech Clinical Trials ETF made up 0.46% of Kera Capital Partners's portfolio in Q1 2026, its #46 holding.
Kera Capital Partners first reported a position in Virtus Biotech Clinical Trials ETF in Q4 2025 and has held it in 2 quarters since.
20 funds tracked by Wall St. Rank held Virtus Biotech Clinical Trials ETF as of Q1 2026.

Based on Kera Capital Partners's 13F filing for Q1 2026, filed 6 May 2026.